Previous anti-VEGF therapy was documented in 1 eye with actual non-exudative neovascular AMD, and in 11 eyes with actual as non-exudative/non-neovascular classified AMD, but thereof only 4 eyes with a previous anti-VEGF therapy during the last 12 months. This evidence concerns the gene VEGFA and age-related macular degeneration.